Jude Uzonwanne
About Jude Uzonwanne
Independent director since April 16, 2021, with a career in life sciences strategy and transactions across consulting and operating roles. He is currently an independent consultant (formerly COO/Senior Adviser at Miralogx LLC, 2022–2024), and previously served as CEO of Mira Pharmaceuticals (2022–2023), Chief Business Officer at 54gene (2021–2022), and held senior consulting roles at ZS Associates, IQVIA, and EY‑Parthenon. He holds a double Honors B.A. in Economics and Political Science from Swarthmore College. Core credentials: corporate strategy, healthcare deal advisory, and global life sciences operating experience .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Miralogx LLC | Independent consultant; previously COO/Senior Adviser | Jun 2022 – Dec 2024 | Operating leadership and advisory in life sciences services . |
| Mira Pharmaceuticals, Inc. | Chief Executive Officer | Jun 2022 – Apr 2023 | Led early-stage biopharma; focus on oral cannabinoid analog development . |
| 54gene, Inc. | Chief Business Officer | Mar 2021 – Jun 2022 | Built genomics-driven healthcare partnerships and pipelines . |
| ZS Associates, Inc. | Principal | Jan 2021 – Mar 2021 | Strategy work across PE/healthcare/tech clients . |
| IQVIA, Inc. | Principal | 2018 – 2020 | Led US Financial Investors Consulting; managed top-6 pharma consulting engagement . |
| EY‑Parthenon LLP | Vice President (Associate Partner) | 2016 – 2018 | Commercial due diligence and growth strategy for healthcare/PE clients . |
| Bain & Company; Dalberg; Bill & Melinda Gates Foundation; Monitor Group | Senior consulting/strategy roles (incl. Deputy Director, Strategy at Gates Foundation) | Prior to 2016 | Global strategy, M&A, and growth programs across markets . |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Bonita Foods (private) | Director | Since 2019 | Privately held specialty foods company; emerging markets focus . |
Board Governance
| Committee | Role | Independence Status | Source/Period |
|---|---|---|---|
| Nominating & Corporate Governance | Chair | Committee members independent under Nasdaq rules | MYMD 10-K/2022 and related governance disclosures (predecessor entity), listing Uzonwanne as Chair . |
| Audit Committee | Member | Committee independent; includes an audit committee financial expert (Bill J. White) | MYMD DEF 14A/2023 and 10-K/2022 . |
| Compensation Committee | Member | Committee independent | MYMD 10-K/2022 . |
| Risk & Disclosure Committee | Member | Committee independent | MYMD 10-K/2022 . |
- The company’s April 2025 proxy (predecessor ticker) continues to identify Uzonwanne as a director, confirming ongoing board service into 2025 .
Fixed Compensation
- Director cash retainers, chair fees, and meeting fees were not detailed in the October 20, 2025 special proxy nor the cited filings. The equity plan share pool increase for director and employee grants was approved on Nov 14, 2025 (see “Performance Compensation”) .
Performance Compensation
Director equity is primarily via RSUs and options under the 2021 Equity Incentive Plan.
| Item | Details |
|---|---|
| Equity Plan Pool (post-amendment) | Increased by 1,375,000 shares to a total of 1,400,000 shares; stockholders approved Nov 14, 2025 . |
| 2021 RSU Grant (company-wide design affecting directors) | 484 RSUs granted on Oct 14, 2021 to then-current six directors and seven key employees; grant-date fair value per RSU: $24,270. Vesting conditioned on market cap and stock price hurdles (see below). As of Sep 30, 2025, no milestones had vested . |
| RSU Performance Metrics | - 33% vests if market cap ≥ $500M for 10 trading days in any 20-day window on/after Dec 15, 2021 and stock price ≥ $150 during that period; - 33% at ≥ $750M and ≥ $150; - 34% at ≥ $1B and ≥ $150; acceleration on change in control or qualifying termination . |
| RSU Status (9/30/2025) | None of the RSU milestones had been met; unamortized RSU value $11,746,680 remained . |
| Director Option Expense (2025 YTD) | Options issued to directors recognized as expense of $110,168 for the nine months ended Sep 30, 2025 (aggregate) . |
Other Directorships & Interlocks
- Public company directorships: none disclosed for Uzonwanne in the cited filings .
- Private board: Bonita Foods (see External Roles) .
- No related-party or interlocking directorship conflicts disclosed for Uzonwanne in the cited documents.
Expertise & Qualifications
- Education: Swarthmore College, double Honors B.A. Economics & Political Science .
- Domain expertise: life sciences strategy, commercial due diligence, global market growth; experience across oncology, rare/specialty disease, CNS, reproductive health, cardiology, diabetes, kidney disease as a corporate strategy/transactions adviser .
- Governance: Chair of Nominating & Corporate Governance Committee (predecessor entity); member of Audit, Compensation, and Risk & Disclosure Committees, all designated independent under Nasdaq standards .
Equity Ownership
- The October 20, 2025 special proxy disclosed beneficial ownership for certain executives and directors, but did not enumerate Uzonwanne’s line-item holdings in the excerpted table provided. Company-wide director equity exposure exists via the 2021 RSU grant and options noted above .
Governance Assessment
- Strengths: independent status; chairs Nominating & Corporate Governance; breadth of life sciences and transaction experience; service on Audit and Compensation supports board effectiveness in oversight of financial reporting and pay practices .
- Alignment and incentives: director equity is largely performance-contingent (market cap/price RSUs), with no vesting as of 9/30/2025—aligns long-term outcomes with shareholders .
- Watch items for investors: significant expansion of equity plan capacity to 1.4M shares and complex capital structure (multiple preferred series, anti-dilution, and extensive warrants) increase dilution risk; robust committee oversight (including by independent directors) will be important as awards are made and capital actions continue .